# Encaleret PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/encaleret

> The PDUFA target action date for encaleret, sponsored by BridgeBio Pharma, Inc. (BBIO), is May 8, 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the encaleret PDUFA date?

The PDUFA target action date for encaleret, sponsored by BridgeBio Pharma, Inc. (BBIO), is May 8, 2027. Status: scheduled. Press release filed with the SEC (EX-99): "Encaleret for ADH1 PDUFA date set for May 8, 2027, with Priority Review; MAA submitted to EMA U.S. launch upon FDA approval" Last confirmed October 29, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/encaleret)

Source: Press release filed with the SEC (EX-99), accession 0001743881-26-000033, https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm (retrieved 2026-11-12). Last confirmed 2026-10-29. Cite: https://sec-api.dev/pdufa/encaleret#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | encaleret |
| Codes |  |
| Sponsor | BridgeBio Pharma, Inc. (BBIO) https://sec-api.dev/companies/bbio/catalysts |
| Indications | adh1, the efficacy, safety, individuals living with autosomal dominant hypocalcemia type 1, chronic hypoparathyroidism in 2026 |
| Modality |  |
| FDA designations | fast track, orphan, priority review |

## Timeline

### October 29, 2025: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3.
- First seen 2025-01-13, last confirmed 2026-02-24.
- Press release filed with the SEC (EX-99) (accession 0001140361-25-039705): "PALO ALTO, CA - October 29, 2025 - BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced positive topline results from" https://www.sec.gov/Archives/edgar/data/1743881/000114036125039705/ef20057894_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-000943): "Topline Results Expected 2H 2025 We have fully enrolled the Phase 3 study (CALIBRATE) of encaleret in ADH1 and expect topline results in 2H 2025 Up to 4 years" https://www.sec.gov/Archives/edgar/data/1743881/000114036125000943/ef20041481_ex99-2.htm
- SEC Form 10-K (accession 0000950170-25-024119): "Topline results from this Phase 3 registrational study are anticipated in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1743881/000095017025024119/bbio-20241231.htm
- SEC Form 10-K (accession 0001743881-26-000009): "•Positive Phase 3 results for encaleret in ADH1: In October 2025, we presented topline results from the Phase 3 CALIBRATE trial of encaleret in autosomal dominant hypocalcemia type 1, which demonstrated statistically significant normalization of serum and urinary calcium versus standard of care." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000009/bbio-20251231.htm
- SEC Form 10-K (accession 0001743881-26-000009): "In October 2025, we reported positive data from our Phase 3 topline results for encaleret in patients with ADH1." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000009/bbio-20251231.htm

### Q1 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: chronic hypoparathyroidism in 2026.
- First seen 2025-10-29, last confirmed 2025-10-29.
- Press release filed with the SEC (EX-99) (accession 0001743881-25-000010): "•The Company plans to initiate a registrational clinical trial of encaleret in pediatric ADH1 in the first quarter of 2026" https://www.sec.gov/Archives/edgar/data/1743881/000174388125000010/bbio-20250930xex991.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-039705): "- BridgeBio plans to initiate registrational studies of encaleret in chronic hypoparathyroidism and pediatric ADH1 in 2026" https://www.sec.gov/Archives/edgar/data/1743881/000114036125039705/ef20057894_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-039705): "In addition, BridgeBio plans to initiate a registrational trial of encaleret in pediatric ADH1 in Q1 2026 and a Phase 3 study of encaleret in adults with chronic hypoparathyroidism in 2026." https://www.sec.gov/Archives/edgar/data/1743881/000114036125039705/ef20057894_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-039705): "These forward-looking statements, including express and implied statements relating to the Phase 3 topline results for encaleret in patients with ADH1, the efficacy, safety and the clinical and therapeutic potential of encaleret, our plans to submit a New Drug Application for encaleret to the FDA in the first half of 2026, and to apply for Marketing Authorization Application to the EMA; our plans to initiate registrational studies of encaleret in chronic hypoparathyroidism and pediatric ADH1 in 2026, and the statements regarding the potential clinical benefits of encaleret for patients in the quotes of Dr. Mannstadt, Ms." https://www.sec.gov/Archives/edgar/data/1743881/000114036125039705/ef20057894_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001743881-25-000010): "•The Company also plans to initiate a Phase 3 study of encaleret in chronic hypoparathyroidism in 2026." https://www.sec.gov/Archives/edgar/data/1743881/000174388125000010/bbio-20250930xex991.htm

### 1H 2026: NDA/BLA submission

- Status: scheduled. Date confidence: half. Stage: 3. Indication: ADH1, the efficacy, safety.
- First seen 2025-10-29, last confirmed 2026-05-07.
- Press release filed with the SEC (EX-99) (accession 0001140361-25-039705): "These forward-looking statements, including express and implied statements relating to the Phase 3 topline results for encaleret in patients with ADH1, the efficacy, safety and the clinical and therapeutic potential of encaleret, our plans to submit a New Drug Application for encaleret to the FDA in the first half of 2026, and to apply for Marketing Authorization Application to the EMA; our plans to initiate registrational studies of encaleret in chronic hypoparathyroidism and pediatric ADH1 in 2026, and the statements regarding the potential clinical benefits of encaleret for patients in the quotes of Dr. Mannstadt, Ms." https://www.sec.gov/Archives/edgar/data/1743881/000114036125039705/ef20057894_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001743881-26-000018): "•The Company intends to submit an NDA to the FDA in the first half of 2026, followed by a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in the second half of the year." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000018/bbio-2026331xex991.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-039705): "- NDA submission planned in the first half of 2026 to support full approval" https://www.sec.gov/Archives/edgar/data/1743881/000114036125039705/ef20057894_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-039705): "The Company intends to submit its New Drug Application (NDA) to the FDA in the first half of 2026, and a Marketing Authorization Application to the EMA to follow." https://www.sec.gov/Archives/edgar/data/1743881/000114036125039705/ef20057894_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001743881-25-000010): "-Company intends to submit an NDA to the FDA in first half of 2026 to support a full approval" https://www.sec.gov/Archives/edgar/data/1743881/000174388125000010/bbio-20250930xex991.htm
- Press release filed with the SEC (EX-99) (accession 0001743881-25-000010): "•BridgeBio intends to submit a NDA to the FDA in the first half of 2026, and a Marketing Authorization Application to the European Medicines Agency to follow." https://www.sec.gov/Archives/edgar/data/1743881/000174388125000010/bbio-20250930xex991.htm

### 2H 2026: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-02-24, last confirmed 2026-02-24.
- Press release filed with the SEC (EX-99) (accession 0001743881-26-000008): "•The Company also plans to initiate RECLAIM-HP, a Phase 3 study of encaleret in chronic hypoparathyroidism in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000008/bbio-20251231xex9911.htm

### July 22, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: individuals living with autosomal dominant hypocalcemia type 1.
- First seen 2026-07-22, last confirmed 2026-07-22.
- Press release filed with the SEC (EX-99) (accession 0001140361-26-029291): "PALO ALTO, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced the FDA has accepted for filing its New Drug Application (NDA) for encaleret for the treatment of individuals living with autosomal dominant hypocalcemia type 1 (ADH1)." https://www.sec.gov/Archives/edgar/data/1743881/000114036126029291/ef20078442_ex99-1.htm

### late 2026: NDA/BLA submission

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-02-24, last confirmed 2026-02-24.
- Press release filed with the SEC (EX-99) (accession 0001743881-26-000008): "-On track for a 1H 2026 NDA submission following positive Phase 3 CALIBRATE results for encaleret in ADH1 and successful completion of a pre-NDA meeting with FDA; U.S. launch anticipated in late 2026/early 2027" https://www.sec.gov/Archives/edgar/data/1743881/000174388126000008/bbio-20251231xex9911.htm

### May 8, 2027: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-07-22, last confirmed 2026-10-29.
- Press release filed with the SEC (EX-99) (accession 0001743881-26-000033): "Encaleret for ADH1 PDUFA date set for May 8, 2027, with Priority Review; MAA submitted to EMA U.S. launch upon FDA approval" https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm
- Press release filed with the SEC (EX-99) (accession 0001743881-26-000033): "•The FDA accepted the Company's NDA for encaleret and granted Priority Review, assigning a PDUFA target action date of May 8, 2027." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-26-029291): "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of May 8, 2027, and BridgeBio is prepared to launch encaleret upon approval, representing a potential blockbuster opportunity for the Company." https://www.sec.gov/Archives/edgar/data/1743881/000114036126029291/ef20078442_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001743881-26-000026): "Encaleret for ADH1 PDUFA date set for May 8, 2027 with Priority Review; MAA submitted to EMA Launch upon FDA approval" https://www.sec.gov/Archives/edgar/data/1743881/000174388126000026/bbio-20260630xex991.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-26-029291): "- PDUFA target action date of May 8, 2027" https://www.sec.gov/Archives/edgar/data/1743881/000114036126029291/ef20078442_ex99-1.htm
- SEC Form 10-Q (accession 0001743881-26-000034): "The FDA accepted our NDA for filing, granted Priority Review and assigned a PDUFA target action date of May 8, 2027, for encaleret." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000034/bbio-20260930.htm
- SEC Form 10-Q (accession 0001743881-26-000027): "The FDA accepted our NDA for filing and assigned a PDUFA target action date of May 8, 2027 for encaleret." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000027/bbio-20260630.htm
- Press release filed with the SEC (EX-99) (accession 0001743881-26-000026): "•The FDA re-considered its review designation of the Company's NDA filing for encaleret in ADH1 and has granted Priority Review, with a PDUFA target action date of May 8, 2027." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000026/bbio-20260630xex991.htm

### 2H 2027: PDUFA date

- Status: scheduled. Date confidence: half.
- First seen 2026-10-29, last confirmed 2026-10-29.
- Press release filed with the SEC (EX-99) (accession 0001743881-26-000033): "- Encaleret for ADH1 has a May 8, 2027 PDUFA date, with Priority Review, and the MAA is under EMA review with potential EU approval in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm

### early 2028: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-10-29, last confirmed 2026-10-29.
- Press release filed with the SEC (EX-99) (accession 0001743881-26-000033): "Encaleret for chronic hypoparathyroidism First participant dosed in RECLAIM-HP, registrational Phase 3 study Topline data anticipated early 2028" https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm
- Press release filed with the SEC (EX-99) (accession 0001743881-26-000033): "Topline data are expected in early 2028, representing a potential second indication in an estimated population of 200,000 patients in the U.S. and EU" https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm
- Press release filed with the SEC (EX-99) (accession 0001743881-26-000033): "Topline results from the study are anticipated in early 2028." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm

Calendar months: [May 2027](https://sec-api.dev/fda-calendar/2027-05)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/encaleret.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Encaleret PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/encaleret

```bibtex
@misc{secapidev_pdufa_encaleret_20261116,
  title        = {Encaleret PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/encaleret}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_encaleret_20261116","title":"Encaleret PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/encaleret","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
